Table 1.
Published clinical trials with RET-inhibitors including breast cancer patients.
| Disease | Trial Identifier | Pts | Receptors status | Intervention | Phase | Endpoints and Results |
|---|---|---|---|---|---|---|
| Advanced Solid Tumors | NCT00940225 | 45 | ER+/HER2- n=35 ER+/HER2+ n= 7 ER+/HER2u n=1 TN n=2 |
Cabozantinib | II | ORR (13.6%) PFS (4.3 m) OS (11.4 m) |
| Breast cancer | NCT01441947 | 52 | ER+/PgR+ n=40 ER+/PgR- n=12 |
Cabozantinib | II | Bone scan RR (38.5%) DCR (50%) OS (19.6 m) PFS (4.3 m) |
| Breast cancer | NCT02562118 | 47 | ER+/PgR+ n=40 ER+/PgR- n=6 |
Lenvatinib + Letrozole | Ib/II | ORR (23.3%) |
| Breast cancer | NCT00811369 | 129 | HR+ n=123 HER2+ n= 6 |
Vandetanib + Fulvestrant | II | uNTx PFS (5.8 m) OS |
| Breast cancer | NCT04002284 | 26 | HR+ n=16 HR- n= 10 |
Anlotinib | II | ORR (15.3%) PFS (5.22 m) DCR (80.7%) |
Pts, number of patients; HER2u, HER2 unknown; PFS, progression-free survival; ORR, overall response rate; DFS, disease-free survival; OS, overall survival; uNTx, urinary N-telopeptide; Bone scan RR, Bone scan response rate.